Arrowhead Pharmaceuticals, Inc. ARWR 深 滬
已收盤 11-06 16:00:00 美东时间
58.16
+0.700
+1.22%
華盛通- 最 高58.71
- 今 開58.21
- 成交量 136.32万股
- 最 低 57.00
- 昨 收 57.46
- 總市值 82.15亿
- 52周最高 95.4899
- 市盈率 靜 --
- 換手率 0.97%
- 52周最低 37.06
- 委 比 77.97%
- 總股本 1.41亿
- 歷史最高 95.4899
- 量 比 0.95
- 振 幅 2.98%
- 歷史最低 1.22
- 每 手 1
- 風險率 11.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arrowhead Pharmaceuticals’ REDEMPLO Receives UK Marketing Authorization For Familial Chylomicronaemia Syndrome; NICE Recommends NHS Funding In England And Wales For Eligible Adults With Genetically Confirmed FCS
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients with Familial Chylomicronaemia Syndrome (FCS) diagnosed via genetic testing or clinical criteria1 The...
10-27 23:40
美股大行评级 | 潜在涨幅279.75%！Jones Trading维持Contineum Therapeutics(CTNM)"买入"评级，目标价上调至30美元
今日重点评级关注：Jones Trading：维持Contineum Therapeutics"买入"评级，目标价从24美元升至30美元；StoneX：维持Forum Markets"投机性买入"评级，目标价从9美元升至12美元
10-16 12:30
Arrowhead Announces Interim Results From Ongoing Phase 1/2a Study Of ARO-MAPT, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Alzheimer’s Disease And Other Tauopathies
Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injection ARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on Day 105, with a maximum individual reduction of 85%, supporting the potential f...
10-14 19:32
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.
09-24 19:51
美股周涨跌榜 | AI医疗概念周内狂飙！Tempus AI劲升32%，CEO释放长期增长指引；TWST升31%
AI医疗概念周内狂飙！Tempus AI劲升32%，CEO释放长期增长指引；TWST升31%，与礼来TuneLab达成合作；FPS升24%，2027财年业绩指引大超预期>>
09-20 09:30
Arrowhead Achieves Clinical Validation for New Drug Platform
Arrowhead Pharmaceuticals (NASDAQ:ARWR) on Tuesday shared interim topline clinical data from a Phase 1/2a trial. The trial is evaluating ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperli...
09-16 19:39
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108
Citigroup analyst Eric Joseph initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $108.
09-09 00:04
